Aggressive Variants of Castration Resistant Prostate Cancer
Abstract: A subset of patients with advanced castration resistant prostate cancer (CRPC) may eventually evolve into an androgen receptor (AR) independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly rising serum prostate specific antigen (PSA) level (1, 2) . Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas. These aggressive tumors often demonstrate low or absent AR protein expression, and in some cases express markers of neuroendocrine differentiation. Since tumor morphology is not always predicted by clinical behavior, the terms "anaplastic prostate cancer" or "neuroendocrine prostate cancer" have been employed descriptively to describe these rapidly growing clinical features. Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum based chemotherapy treatment regimens (3) . Therefore, understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications.
On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathological classification of neuroendocrine prostate cancer (NEPC).
The committee consisted of genitourinary oncologists, urologists, urological surgical pathologists, basic scientists, and translational researchers, with expertise in this field. One area that was extensively discussed was whether transformation to anaplastic/ neuroendocrine prostate cancer is related to therapy. Aggressive variants of prostate cancer are increasingly recognized in the clinic. This could be due to greater awareness, patients living longer due to Author Manuscript Published OnlineFirst on April 11, 2014; DOI: 10.1158/1078-0432.CCR-13-3309 more effective therapies and followed for their natural history of disease, or the development of NEPC as a mechanism of resistance to current therapies. Recent clinical experience and preclinical data suggest that transformation to AR independent prostate cancer likely occurs as one potential mechanism of adaptive resistance to AR targeted therapies in a minority of patients.
While this may be the case, anecdotal experiences were discussed in which patients with anaplastic or small cell neuroendocrine prostate cancer responded to androgen deprivation or newer AR targeted therapies; thus, clinical heterogeneity can be observed even between patients with this disease. In practice and depending on the clinical scenario, we often recommend hormonal therapy first or concurrently with chemotherapy. The group, due to absence of data, discouraged the term "therapy related" neuroendocrine or small cell prostate cancer due to concern that clinicians or patients may withhold potentially effective hormonal therapies concerned that it could make things worse. It was generally thought that hormonal therapy should be considered in the appropriate clinical context.
There are deficiencies associated with the currently used terminologies. "Anaplastic prostate cancer" is not generally accepted by surgical pathologists, because the term anaplastic is a well recognized histopathologic term used to denote pleomorphic cytology. Although anaplastic in this setting is used to describe clinical features and does not require pathology, using the term anaplastic implies a histologic correlate when it is not typically present within this disease spectrum. "Neuroendocrine prostate cancer" is also debated as an appropriate term to describe this clinical phenotype, as the term is currently not well defined and implies that small cell carcinoma or a predominantly neuroendocrine histology must be seen on biopsy, when it is clear that many cases with this clinical phenotype do not demonstrate classical morphology or 
One of the major limitations in the past for studying advanced prostate cancer has been the lack of post-treatment biopsies. The importance of collection of tumor samples for molecular profiling from patients at various time points during therapy and progression is a significant area of need in clinically identifying patients undergoing transformation and in understanding the molecular mechanisms underlying trans-differentiation. Biopsy should be considered for diagnostic purposes in patients with CRPC that develop rapid progression (especially to visceral organs such as brain or liver) in the setting of a low or modestly elevated serum PSA level. Markers include chromogranin, synaptophysin, CD56, neuron specific enolase (NSE), bombesin, though none are diagnostic or particularly reliable, and are contingent on the specificity of the antibodies and the thresholds for visual interpretation of the staining. Expert pathologists surveyed at the Workshop generally agreed that of these commonly used IHC markers, synaptophysin is most sensitive and chromogranin A is most specific for NEPC. CD44 is a cell surface adhesion molecule highly expressed in cancer stem cells and in NEPC (14) and associated with tumor metastasis (15, 16) , suggesting that there may be stem cell-like functions of neuroendocrine cells in prostate cancer and potentially reversion to a primitive stem like state in pure NEPC. Induction of neuronal differentiation regulators and genes associated with a neural phenotype are also commonly seen in NEPC. These include ASCL1(17), MYCN (6) , and others associated with axon guidance and synapse signaling (17, 18) . Furthermore, reduced expression of the transcription factor REST, a repressor of neuronal differentiation, is commonly observed in NEPC, associated with up-regulation of neuronal genes, and is implicated as a key regulator in driving NEPC disease progression (18) . New data was also presented at the Workshop evaluating gene expression profiles of NEPC cell lines and tumors from published datasets, revealing that NEPC tends to be highly proliferative with Ki67 rates of >50%. Although not routinely assessed, Ki67 is sometimes utilized by expert pathologists to support the diagnosis. Recent work has identified several cell cycle genes as frequently amplified and/or overexpressed in NEPC including UBE2C, cyclin D1, AURKA, AURKB, and PLK1 (6, 24) . Altered mitotic programs likely play a role in driving uncontrolled growth and disease progression. Importantly the cell cycle aurora kinases, polo like kinase (PLK1), as well as RB1 are potentially targetable and may represent novel therapeutic targets for NEPC. Furthermore, elucidating how these molecular markers or others may predict platinum sensitivity and how they may associate with response or resistance to other treatments for CRPC such as taxanes warrants further study. The histone deacetylase EZH2 is also highly expressed in NEPC (6, 25) and hypermethylation of key genes within the NEPC genome may be associated with the cellular plasticity seen during transdifferentiation; the role of epigenetic modification in promoting NEPC progression is an area of research (Beltran, Rubin, and colleagues, unpublished data). The role of the tumor microenvironment and data supporting MET as a potential targetable driver of NEPC was also presented as an area of active investigation (Tomlins and colleagues, unpublished data).
In the last few years, there have been significant advances in our understanding and treatment of patients with advanced prostate cancer. With the widespread clinical introduction of new effective systemic therapies, patients are living longer. Recognizing that we now have choices, it becomes essential to understand variants within the spectrum of CRPC in order to select patients for appropriate therapies. Neuroendocrine or anaplastic prostate cancer is one important variant and these patients may be considered for platinum chemotherapy or clinical trial enrollment. 
